Clinical Trials
9
Active:2
Completed:7
Trial Phases
2 Phases
Phase 2:1
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (83.3%)Phase 2
1 (16.7%)Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 21
- Registration Number
- NCT02342184
- Locations
- 🇯🇵
Department of Neurology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 99
- Registration Number
- NCT02184741
- Locations
- 🇯🇵
Japan Blood Products Organization, Tokyo, Japan
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 17
- Registration Number
- NCT02032095
- Locations
- 🇯🇵
Japan Blood Products Organization, Tokyo, Japan
Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
Phase 3
Completed
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Drug: Placebo of GB-0998
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Japan Blood Products Organization
- Target Recruit Count
- 26
- Registration Number
- NCT00335985
- Locations
- 🇯🇵
Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
News
No news found